MorphoSys and Incyte Corporation announced that their joint collaboration and license agreement for the further development and global commercialization of MorphoSys’ investigational compound tafasitamab has received antitrust clearance.
Incyte is based near Wilmington.
The agreement triggers the $750 million upfront payment by Incyte to MorphoSys, as well as Incyte’s equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS).
The U.S. Food and Drug Administration (FDA) recently accepted filing of MorphoSys’ Biologics License Application (BLA) for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma and granted Priority Review.
B-cell lymphoma is a blood cancer in the lymph nodes.
In January MorphoSys and Incyte Corporation entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. In the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, outside the U.S. Incyte will have exclusive commercialization rights.
Tafasitamab is being clinically investigated as a therapeutic option combination.
